Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 5, 2014 to file lead plaintiff applications in a securities class action lawsuit against Galena Biopharma, Inc. (NASDAQ:GALE), if they purchased the Company’s securities during the period between November 6, 2013 and February 14, 2014, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Oregon. Galena Biopharma Inc (NASDAQ:GALE) shares after opening at $2.63 on last trade day and at the end of the day closed at $2.82. Company price to sales ratio in past twelve months was calculated as 205.20 and price to cash ratio as 5.54. Galena Biopharma Inc (NASDAQ:GALE) showed a negative weekly performance of -15.82%.
Oxygen Biotherapeutics, Inc., (NASDAQ:OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced that it has priced an underwritten public offering of shares of common stock at a public offering price of $5.60 per share for gross proceeds of approximately $52 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company. The Company has also granted the underwriters a 45-day option to purchase up to an additional 1,392,857 shares of common stock to cover over-allotments, if any. Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) shares fell -8.53% in last trading session and ended the day on $5.68. OXBT return on assests ratio is recorded as -380.60%. Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) yearly performance is 8.40%.
OXiGENE Inc (NASDAQ:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, reported financial results for the year ended December 31, 2013. Commented Peter Langecker, M.D., Ph.D., OXiGENE’s Chief Executive Officer: “During the past year, we have made significant progress in advancing our pipeline of vascular disrupting agents (VDAs), led by ZYBRESTAT(R) in ovarian cancer, and we are very pleased to be moving forward with a Phase 2 development program for ZYBRESTAT in neuroendocrine tumors, a rare tumor type with few treatment options.” OXiGENE Inc (NASDAQ:OXGN) shares moved up 5.87% in last trading session and was closed at $4.01, while trading in range of $4.01 – $4.40. OXiGENE Inc (NASDAQ:OXGN) year to date (YTD) performance is 59.13%.
Coronado Biosciences, Inc. (NASDAQ:CNDO) announced its financial results for the fourth quarter and year ended December 31, 2013. Financial Highlights: Coronado reported a net loss of $9.8 million, or $0.27 per share, for the fourth quarter of 2013 compared to a net loss of $8.7 million, or $0.36 per share, for the fourth quarter of 2012. Research and development expenses were $25.7 million for the year ended December 31, 2013, compared to $17.5 million for 2012. General and administrative expenses totaled $10.1 million for the year ended December 31, 2013, compared to $8.7 million for 2012. In 2013, the increase in research and development expenses was due to expenses related to the TSO clinical program and the increase in general and administrative expenses related to incremental personnel-related costs from the elimination of certain executive positions and the departure of Coronado’s previous CEO. Coronado Biosciences Inc (NASDAQ:CNDO) weekly performance is -21.32%. On last trading day company shares ended up $2.03. Coronado Biosciences Inc (NASDAQ:CNDO) distance from 50-day simple moving average (SMA50) is -24.86%. Analysts mean target price for the company is $1.90.